William Vainchenker

William Vainchenker's AcademicInfluence.com Rankings

William Vainchenker

Philosophy

#4700

World Rank

#7316

Historical Rank

Logic

#2106

World Rank

#3021

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is William Vainchenker Influential?

(Suggest an Edit or Addition)

According to Wikipedia, William Vainchenker, born on 16 December 1947, is a French medical doctor and researcher. He is considered a specialist in hematopoiesis. Biography William Vainchenker is director of research at Inserm, Hematopoiesis and Stem Cells Unit, Gustave Roussy Institute, Villejuif.

(See a Problem?)

William Vainchenker's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera (2005) (2656)
Mutation in TET2 in myeloid cancers. (2009) (1332)
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. (2011) (828)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. (2005) (718)
c-Mpl ligand is a humoral regulator of megakaryocytopoiesis (1994) (682)
Prognostic score including gene mutations in chronic myelomonocytic leukemia. (2013) (467)
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. (2006) (452)
JAK/STAT signaling in hematological malignancies (2013) (427)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis (2009) (421)
Megakaryocytic and erythrocytic lineages share specific transcription factors (1990) (406)
New mutations and pathogenesis of myeloproliferative neoplasms. (2011) (399)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. (2017) (392)
Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. (1993) (366)
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. (2004) (348)
Platelet formation is the consequence of caspase activation within megakaryocytes. (2002) (345)
Specific involvement of caspases in the differentiation of monocytes into macrophages. (2002) (342)
Mutations of ASXL1 gene in myeloproliferative neoplasms (2009) (330)
Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. (2011) (303)
Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy (2004) (303)
The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. (1995) (298)
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. (2010) (277)
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). (2009) (277)
A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38- progenitor cells in long-term cultures and semisolid assays (1993) (267)
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. (2016) (264)
High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. (1997) (264)
Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily. (2000) (258)
Expression of tal-1 and GATA-binding proteins during human hematopoiesis. (1993) (241)
Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. (1996) (241)
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. (2006) (239)
Clonal architecture of chronic myelomonocytic leukemias. (2013) (239)
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. (2006) (238)
The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. (2000) (238)
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia (2009) (232)
Expression of platelet membrane glycoproteins and alpha‐granule proteins by a human erythroleukemia cell line (HEL). (1984) (231)
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases (2014) (230)
Acquired initiating mutations in early hematopoietic cells of CLL patients. (2014) (230)
Biosynthesis of major platelet proteins in human blood platelets. (1987) (228)
Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. (1989) (224)
Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. (1982) (220)
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. (2016) (217)
Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. (2002) (216)
The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. (2001) (210)
Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. (1993) (205)
Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. (2006) (204)
Spi-1/PU.1 transgenic mice develop multistep erythroleukemias (1996) (200)
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. (2007) (199)
Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells. (1996) (199)
Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. (1997) (198)
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. (2004) (187)
Apoptosis regulation in tetraploid cancer cells (2006) (186)
Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. (2008) (185)
Endomitosis of human megakaryocytes are due to abortive mitosis. (1998) (183)
BCR-ABL down-regulates the DNA repair protein DNA-PKcs. (2001) (178)
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. (2008) (177)
Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation. (1992) (175)
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents (2016) (175)
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. (2007) (173)
Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. (2011) (173)
Regulation of the expression of IL-6 in human monocytes. (1989) (170)
Hematopoietic growth factors and human megakaryocyte differentiation. (1992) (168)
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. (2008) (168)
Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. (2002) (166)
Immunological study of in vitro maturation of human megakaryocytes (1984) (164)
Proplatelet formation is regulated by the Rho/ROCK pathway. (2005) (164)
Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. (2011) (163)
JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation (2005) (163)
FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. (2004) (162)
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. (2010) (162)
A new c‐kit mutation in a case of aggressive mast cell disease (1997) (154)
A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression (2013) (154)
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. (2006) (153)
Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. (2014) (153)
A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. (2009) (150)
Remodeling of Bone Marrow Hematopoietic Stem Cell Niches Promotes Myeloid Cell Expansion during Premature or Physiological Aging (2019) (148)
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis (2006) (143)
Effects of cytokines on platelet production from blood and marrow CD34+ cells. (1998) (141)
RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization (2012) (141)
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. (2016) (140)
Mechanisms of WASp-mediated hematologic and immunologic disease. (2004) (138)
Myeloid and megakaryocytic properties of K-562 cell lines. (1983) (138)
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma (2014) (138)
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. (2007) (138)
Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers (2002) (138)
Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens. (2006) (137)
Defective alpha-granule production in megakaryocytes from gray platelet syndrome: ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. (1981) (134)
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. (2010) (133)
The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. (2007) (129)
From hematopoietic stem cells to platelets (2007) (129)
Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. (1999) (128)
Interleukin-6 and its receptor are expressed by human megakaryocytes: in vitro effects on proliferation and endoreplication. (1991) (127)
A monoclonal antibody against an erythrocyte ontogenic antigen identifies fetal and adult erythroid progenitors. (1986) (127)
A lentiviral vector encoding the human Wiskott–Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice (2005) (125)
Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures. (1982) (125)
A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha-granules and chromosome 11 deletion at 11q23. (1995) (123)
A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. (2005) (123)
Individual CD34+CD38lowCD19-CD10- progenitor cells from human cord blood generate B lymphocytes and granulocytes. (1997) (122)
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. (2010) (121)
A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. (2005) (121)
Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. (1992) (118)
Loss of attachment to fibronectin with terminal human erythroid differentiation. (1990) (117)
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. (2013) (116)
Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice. (2006) (116)
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies (2015) (115)
Intracellular Localization and Constitutive Endocytosis of CXCR4 in Human CD34+ Hematopoietic Progenitor Cells (2004) (115)
Activating mutations in human acute megakaryoblastic leukemia. (2008) (114)
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition (2008) (113)
Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. (2009) (112)
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. (2008) (110)
Infection of megakaryocytes by human immunodeficiency virus in seropositive patients with immune thrombocytopenic purpura. (1991) (110)
Regulation of megakaryocyte maturation and platelet formation (2009) (109)
Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. (2007) (108)
RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. (2005) (107)
Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. (1996) (106)
Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. (2005) (106)
Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases (2014) (104)
Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. (2005) (103)
JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms (2012) (103)
EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. (2008) (102)
Expression of platelet proteins during the in vitro and in vivo differentiation of megakaryocytes and morphological aspects of their maturation. (1986) (101)
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders (2018) (100)
Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. (1999) (100)
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution (2014) (99)
Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. (2006) (99)
Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. (2007) (97)
Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. (2012) (97)
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. (2009) (96)
BCR–ABL activates STAT3 via JAK and MEK pathways in human cells (2006) (95)
A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. (2008) (94)
Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice (2007) (93)
Alteration of vimentin intermediate filament expression during differentiation of human hemopoietic cells. (1983) (93)
The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation. (1999) (93)
A Senescence-Like Cell-Cycle Arrest Occurs During Megakaryocytic Maturation: Implications for Physiological and Pathological Megakaryocytic Proliferation (2010) (92)
The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. (2006) (92)
Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells (2010) (91)
Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models (2012) (91)
The value of flow cytometric analysis of platelet glycoprotein expression of CD34+ cells measured under conditions that prevent P-selectin-mediated binding of platelets. (1995) (88)
Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. (1996) (88)
Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. (2006) (88)
Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. (2003) (87)
The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells. (1996) (86)
Differential regulation of actin stress fiber assembly and proplatelet formation by α2β1 integrin and GPVI in human megakaryocytes (2004) (86)
Identification of Lymphomyeloid Primitive Progenitor Cells in Fresh Human Cord Blood and in the Marrow of Nonobese Diabetic–Severe Combined Immunodeficient (NOD-SCID) Mice Transplanted with Human CD34+ Cord Blood Cells (1999) (86)
Murine stromal cells counteract the loss of long-term culture-initiating cell potential induced by cytokines in CD34(+)CD38(low/neg) human bone marrow cells. (1999) (85)
Characterization of hematopoietic progenitors from human yolk sacs and embryos. (1995) (85)
Megakaryocyte polyploidization is associated with a functional gene amplification. (2003) (85)
Applying ecological and evolutionary theory to cancer: a long and winding road (2012) (83)
A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. (2003) (83)
Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. (2015) (81)
Retrovirus-mediated gene transfer into human CD34+38low primitive cells capable of reconstituting long-term cultures in vitro and nonobese diabetic-severe combined immunodeficiency mice in vivo. (1998) (81)
Megakaryocyte colony formation from human bone marrow precursors (1979) (80)
Human platelet alpha granules contain a nonspecific inhibitor of megakaryocyte colony formation: Its relationship to type β transforming growth factor (TGF‐β) (1988) (79)
In vitro effects of hematopoietic growth factors on the proliferation, endoreplication, and maturation of human megakaryocytes. (1991) (79)
Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates. (2001) (79)
An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia (2009) (79)
Uncoordinated expression of fibrinogen compared with thrombospondin and von Willebrand factor in maturing human megakaryocytes. (1989) (79)
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. (2002) (78)
Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. (2005) (77)
Gray platelet syndrome: immunoelectron microscopic localization of fibrinogen and von Willebrand factor in platelets and megakaryocytes (1985) (77)
Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. (1995) (76)
Expression of CD4 by human hematopoietic progenitors. (1994) (76)
RNA Interference Shows Critical Requirement for NF-κB p50 in the Production of IL-12 by Human Dendritic Cells1 (2003) (76)
Role of p21(Cip1/Waf1) in cell-cycle exit of endomitotic megakaryocytes. (2001) (76)
Simultaneous detection of membrane markers with monoclonal antibodies and peroxidatic activities in leukaemia: ultrastructural analysis using a new method of fixation preserving the platelet peroxidase (1984) (75)
Oncogenic mechanisms in myeloproliferative disorders (2006) (75)
Inhibition of insulin receptor binding by phorbol esters. (1982) (75)
Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. (1996) (75)
Lipofectamine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells. (1998) (74)
p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. (2005) (74)
Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. (1990) (74)
Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. (2018) (73)
Role of human immunodeficiency virus replication in defective in vitro growth of hematopoietic progenitors (1992) (73)
MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. (2009) (73)
MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. (2012) (72)
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. (2010) (72)
Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro (2012) (72)
Erythropoietin induces the association of phosphatidylinositol 3'-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor. (1993) (71)
Orientation‐specific signalling by thrombopoietin receptor dimers (2011) (71)
A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene. (2014) (70)
Microarray Analysis of LIF/Stat3 Transcriptional Targets in Embryonic Stem Cells (2005) (69)
Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. (2000) (69)
Growth of human megakaryocyte colonies in culture from fetal, neonatal, and adult peripheral blood cells: ultrastructural analysis. (1979) (69)
Developmentally regulated expression of a 78 kDa erythroblast membrane glycoprotein immunologically related to the platelet thrombospondin receptor. (1989) (68)
Normal human serum contains a factor(s) capable of inhibiting megakaryocyte colony formation. (1982) (68)
Developmental changes in human megakaryocyte ploidy. (1991) (68)
Heterogeneity in the cellular commitment of a human leukemic cell line: K 562. (1981) (67)
Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells. (2005) (67)
A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38- progenitor cells in long-term cultures and semisolid assays. (1993) (66)
Erythroid properties of K562 cells. Effect of hemin, butyrate and TPA induction. (1983) (66)
Fibrinogen is not synthesized by human megakaryocytes. (1991) (66)
Developmental changes in human megakaryopoiesis (2013) (65)
Immunosuppression by Mutated Calreticulin Released from Malignant Cells. (2019) (64)
The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons. (2014) (64)
Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitro. (1991) (63)
Gray platelet syndrome: immunoelectron microscopic localization of fibrinogen and von Willebrand factor in platelets and megakaryocytes. (1985) (63)
Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. (2013) (63)
Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. (2004) (62)
Granulocyte-macrophage colony-stimulating factor and erythropoietin act competitively to induce two different programs of differentiation in the human pluripotent cell line UT-7. (1992) (62)
Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. (2019) (62)
Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. (2003) (61)
Thrombopoietin receptor is required for the oncogenic function of CALR mutants (2016) (60)
Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes (1990) (59)
Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. (2004) (59)
Megakaryocyte colony formation from human bone marrow precursors. (1979) (59)
CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model (2012) (58)
Transferrin binding to K562 cell line. Effect of heme and sodium butyrate induction. (1982) (57)
Megakaryocyte cultures in the chronic phase and in the blast crisis of chronic myeloid leukaemia: studies on the differentiation of the megakaryocyte progenitors and on the maturation of megakaryocytes in vitro (1982) (57)
Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells (2003) (57)
Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis (2017) (57)
Hydrocortisone differentially affects the ability of murine stromal cells and human marrow-derived adherent cells to promote the differentiation of CD34++/CD38- long-term culture-initiating cells. (1994) (56)
Localization of platelet osteonectin at the internal face of the alpha-granule membranes in platelets and megakaryocytes. (1992) (56)
CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress (2016) (56)
Asymmetrical segregation of chromosomes with a normal metaphase/anaphase checkpoint in polyploid megakaryocytes. (2001) (56)
A partial down-regulation of WASP is sufficient to inhibit podosome formation in dendritic cells. (2006) (55)
Identification of human T‐lymphoid progenitor cells in CD34+CD38low and CD34+CD38+ subsets of human cord blood and bone marrow cells using NOD‐SCID fetal thymus organ cultures (1999) (54)
Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. (2011) (53)
Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7 (2000) (53)
Thrombopoietin does not induce lineage-restricted commitment of Mpl-R expressing pluripotent progenitors but permits their complete erythroid and megakaryocytic differentiation. (1997) (53)
P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. (2008) (53)
Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors (2013) (52)
ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. (2017) (52)
Nerve growth factor is involved in the supportive effect by bone marrow--derived stromal cells of the factor-dependent human cell line UT-7. (1996) (51)
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. (2014) (51)
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. (2007) (51)
Identification of CXCR4 as a New Nitric Oxide‐Regulated Gene in Human CD34+ Cells (2007) (51)
Expression and Function of the Collagen Receptor GPVI during Megakaryocyte Maturation* (2001) (51)
Antiviral agent Cidofovir decreases Epstein–Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies (2003) (51)
Megakaryocyte and polyploidization. (2018) (50)
Early and Persistent Bone Marrow Hematopoiesis Defect in Simian/Human Immunodeficiency Virus-Infected Macaques despite Efficient Reduction of Viremia by Highly Active Antiretroviral Therapy during Primary Infection (2001) (49)
FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. (2007) (49)
TREATMENT OF PURE RED CELL APLASIA BY HIGH DOSE INTRAVENOUS IMMUNOGLOBULINS (1983) (48)
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. (2005) (48)
Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. (2011) (48)
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model (2013) (48)
Murine pluripotent hematopoietic progenitors constitutively expressing a normal erythropoietin receptor proliferate in response to erythropoietin without preferential erythroid cell differentiation (1994) (47)
Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. (2013) (47)
Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. (2010) (47)
Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant (2002) (46)
Expression of CD4 by Human Hematopoietic Progenitors (1994) (46)
Supplementary Figure S1 (2012) (46)
JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. (2014) (45)
The syndrome of T8 hyperlymphocytosis: variation in phenotype and cytotoxic activities of granular cells and evaluation of their role in associated neutropenia. (1987) (45)
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. (2012) (44)
Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin (2016) (44)
Membrane-bound Delta-4 Notch ligand reduces the proliferative activity of primitive human hematopoietic CD34+CD38low cells while maintaining their LTC-IC potential (2004) (44)
Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. (2003) (44)
Inhibition of protein kinase C suppresses megakaryocytic differentiation and stimulates erythroid differentiation in HEL cells. (1996) (44)
Human megakaryocytopoiesis: in vitro regulation and characterization of megakaryocytic precursor cells by differentiation markers. (1988) (44)
NK cell sensitivity of the leukemic K 562 cells; effect of sodium butyrate and hemin induction. (1982) (43)
Interleukin 6 dependence of spontaneous in vitro differentiation of B cells from patients with IgM gammapathy. (1990) (43)
Hematopoietic‐promoting activity of the murine stromal cell line MS‐5 is not related to the expression of the major hematopoietic cytokines (1995) (43)
Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation. (2010) (43)
The abnormal proplatelet formation in MYH9‐related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition (2013) (43)
Role of granulocyte‐macrophage colony‐stimulating factor, Interleukin‐3 and Interleukin‐5 in the eosinophilia associated with T cell lymphoma (1993) (42)
Susceptibility of human bone marrow stromal cells to human immunodeficiency virus (HIV). (1995) (41)
Expression of platelet glycoprotein Ib alpha in HEL cells. (1986) (41)
Cell-cell matrix and cell-cell interactions during hematopoietic differentiation. (1992) (41)
Posttransfusion purpura‐like syndrome associated with CD36 (Naka) isoimmunization (1995) (41)
Notch/Delta4 Interaction in Human Embryonic Liver CD34+ CD38− Cells: Positive Influence on BFU‐E Production and LTC‐IC Potential Maintenance (2005) (40)
Faculty of 1000 evaluation for Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. (2018) (39)
Clonal expression of the Tn antigen in erythroid and granulocyte colonies and its application to determination of the clonality of the human megakaryocyte colony assay. (1982) (39)
Erythropoietin gene transfer and expression in adult normal mice: use of an adenovirus vector. (1994) (39)
A major role of TGF-beta1 in the homing capacities of murine hematopoietic stem cell/progenitors. (2010) (39)
Osteopontin is upregulated by BCR-ABL. (2005) (38)
New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. (2006) (38)
A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm. (2015) (37)
Stromal cells retard the differentiation of CD34(+)CD38(low/neg) human primitive progenitors exposed to cytokines independent of their mitotic history. (2001) (37)
Recent advances in understanding myelofibrosis and essential thrombocythemia (2016) (37)
TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells (2014) (37)
Expression of platelet glycoprotein Ib by cultured human megakaryocytes: ultrastructural localization and biosynthesis. (1990) (37)
The transcription factor Srf regulates hematopoietic stem cell adhesion. (2010) (36)
Immunophenotype of leukemic blasts with small peroxidase-positive granules detected by electron microscopy. (1988) (36)
Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells (1998) (36)
Constitutive expression of GATA-1 interferes with the cell-cycle regulation. (1996) (36)
P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis (2016) (36)
Ultrastructural and cytochemical changes induced by short and prolonged culture of human monocytes. (1980) (35)
Role of human immunodeficiency virus replication in defective in vitro growth of hematopoietic progenitors. (1992) (34)
Expression of interleukin 6 and its specific receptor by untreated and PMA-stimulated human erythroid and megakaryocytic cell lines. (1991) (34)
Immunological characterization of the leukemic megakaryocytic line at light and electron microscopic levels. (1984) (33)
Ultrastructural and cytochemical characterization of blasts from early erythroblastic leukemias. (1987) (33)
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. (2007) (33)
Non-apoptotic functions of caspases in myeloid cell differentiation (2017) (33)
Radiation‐induced expression of functional Fas ligand in EBV‐positive human nasopharyngeal carcinoma cells (2000) (33)
Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy (2018) (32)
TET2, a tumor suppressor in hematological disorders. (2012) (32)
The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development (2010) (32)
Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis (2017) (31)
Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients (2013) (31)
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms (2013) (31)
JAK2, the JAK2 V617F mutant and cytokine receptors. (2007) (31)
Hemin regulates the expression of transferrin receptors in human hematopoietic cell lines (1982) (31)
Effects of granulocyte-macrophage colony-stimulating factor and erythropoietin on leukemic erythroid colony formation in human early erythroblastic leukemias. (1987) (30)
Use of a monoclonal antibody (GA3) to demonstrate lineage restricted O-glycosylation on leukosialin during terminal erythroid differentiation. (1988) (30)
Critical role of the HDAC6–cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect (2017) (30)
In vitro inhibition of normal human hematopoiesis by marrow CD3+, CD8+, HLA-DR+, HNK1+ lymphocytes. (1988) (30)
Inhibition of protein kinase C suppresses megakaryocytic differentiation and stimulates erythroid differentiation in HEL cells (1996) (30)
Structure of the promoter region and tissue specificity of the human glycophorin C gene. (1989) (29)
Retrovirus-mediated transfer of the erythropoietin gene in hematopoietic cells improves the erythrocyte phenotype in murine beta-thalassemia. (1994) (29)
p19INK4d Controls Hematopoietic Stem Cells in a Cell-Autonomous Manner during Genotoxic Stress and through the Microenvironment during Aging (2014) (29)
Caspase-activated ROCK-1 allows erythroblast terminal maturation independently of cytokine-induced Rho signaling (2010) (29)
Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette (2001) (29)
Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. (2009) (29)
Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. (2014) (29)
Absence of mutations in the HoxA10, HoxA11 and HoxD11 nucleotide coding sequences in thrombocytopenia with absent radius syndrome (2002) (29)
Thrombocytopenia after bone marrow transplantation caused by a recipient origin Br(a) allo-antibody: presence of mixed chimerism 3 years after the graft without hematologic relapse. (1994) (29)
Regulation of Id gene expression during embryonic stem cell-derived hematopoietic differentiation. (2000) (29)
Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development (2019) (28)
Thrombopoietin and its receptor. (1998) (28)
Concomitant germ‐line RUNX1 and acquired ASXL1 mutations in a T‐cell acute lymphoblastic leukemia (2013) (28)
Role of tyrosine kinases and phosphatases in polycythemia vera. (2005) (27)
Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene-driven myeloid leukemia. (2019) (27)
Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F‐negative polycythaemia vera patients (2008) (27)
Morphological Abnormalities in Cultured Erythroid Colonies (BFU‐E) from the Blood of Two Patients with HEMPAS (1979) (27)
Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development. (2007) (27)
Thrombocytopenia in HIV infection. (1994) (27)
Major effects of TPO delivered by a single injection of a recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: risk of sustained expression inducing myelofibrosis due to immunosuppression (1998) (27)
The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. (2017) (26)
Ex vivo expanded mobilized peripheral blood CD34+ cells accelerate haematological recovery in a baboon model of autologous transplantation (2000) (25)
Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation (2014) (25)
A 93‐kDa glycoprotein expressed on human cultured monocytes and dendritic reticulum cells defined by an anti‐K562 monoclonal antibody (1986) (25)
Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin1 (2006) (25)
Early expression of glycophorin C during normal and leukemic human erythroid differentiation. (1989) (25)
In vitro infection of bone marrow-adherent cells by human immunodeficiency virus type 1 (HIV-1) does not alter their ability to support hematopoiesis. (1995) (25)
Prominent role of TGF-1 in thrombopoietin-induced myelofibrosis in mice (2002) (24)
Megakaryocytopoiesis: cellular aspects and regulation. (1995) (24)
Pattern of pyruvate kinase isozymes in erythroleukemia cell lines and in normal human erythroblasts. (1984) (24)
Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone. (2014) (24)
Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial (2011) (24)
Presence of the Tn antigen on hematopoietic progenitors from patients with the Tn syndrome. (1985) (24)
Miscreant myeloproliferative disorder stem cells (2008) (24)
Disappearance of Hb F and i antigen during the first year of life (1980) (24)
Imatinib effect on growth and signal transduction in polycythemia vera. (2007) (24)
CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner (2016) (24)
Presence of a defect in karyokinesis during megakaryocyte endomitosis (2012) (24)
Requirement for mitogen-activated protein kinase activation in the response of embryonic stem cell-derived hematopoietic cells to thrombopoietin in vitro. (2002) (23)
New hematopoietic differentiation antigens detected by anti-K562 monoclonal antibodies. (1988) (23)
Limits of phenotypic markers for the diagnosis of megakaryoblastic leukemia. (1989) (23)
Growth and differentiation of the human megakaryoblastic cell line (ELF- 153): a model for early stages of megakaryocytopoiesis (1994) (23)
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features (2008) (23)
TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis. (2016) (23)
Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells. (2002) (23)
Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca-/- mice. (2014) (22)
Human platelet alpha granules contain a nonspecific inhibitor of megakaryocyte colony formation: its relationship to type beta transforming growth factor (TGF-beta). (1988) (22)
Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor. (1994) (22)
Autocrine stimulation by erythropoietin (Epo) requires Epo secretion. (1994) (22)
Regulation of i- and I-antigen expression in the K562 cell line. (1982) (21)
High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin. (1999) (21)
Glycoprotein I identification during normal and pathological megakaryocytic maturation. (1983) (21)
A murine stromal cell line promotes the proliferation of the human factor-dependent leukemic cell line UT-7. (1994) (20)
Megakaryocyte polyploidization: role in platelet production (2020) (20)
Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity. (2019) (20)
[Regulation of erythropoiesis]. (1993) (20)
Therapy‐related leukemia associated with myelofibrosis. Blast cell characterization in six cases (1984) (20)
Molecular pathophysiology of chronic myelogenous leukemia. (1998) (20)
Spi-1 transgenic mice develop a clonal erythroleukemia which does not depend on p53 mutation (1998) (20)
Inhibition of erythroid differentiation and induction of megakaryocytic differentiation by thrombopoietin are regulated by two different mechanisms in TPO-dependent UT-7/c-mpl and TF-1/c-mpl cell lines (1998) (20)
TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event (2008) (20)
Overexpression of the partially activated αIIbβ3D723H integrin salt bridge mutant downregulates RhoA activity and induces microtubule‐dependent proplatelet–like extensions in Chinese hamster ovary cells (2009) (20)
Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN (2020) (19)
Autonomous Megakaryocyte Growth in Essential Thrombocythemia and Idiopathic Myelofibrosis Is Not Related to a c-mpl Mutation or to an Autocrine Stimulation by Mpl-L (1999) (19)
The granulocyte colony‐stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat5 (2001) (19)
Ex vivo expansion marginally amplifies repopulating cells from baboon peripheral blood mobilized CD34+ cells (2002) (19)
Distinct Effects of the Soluble Versus Membrane‐Bound Forms of the Notch Ligand Delta‐4 on Human CD34+CD38low Cell Expansion and Differentiation (2008) (19)
Inhibition of the erythropoietin-induced erythroid differentiation by granulocyte-macrophage colony-stimulating factor in the human UT-7 cell line is not due to a negative regulation of the erythropoietin receptor. (1996) (19)
Thrombopoietin (Mpl-ligand) and the Regulation of Platelet Production (1997) (19)
Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage (2009) (19)
The cell division control protein 42–Src family kinase–neural Wiskott–Aldrich syndrome protein pathway regulates human proplatelet formation (2016) (19)
The Mpl-ligand is involved in the growth-promoting activity of the murine stromal cell line MS-5 on ES cell-derived hematopoiesis. (1998) (19)
The origin of human B and T cells from multipotent stem cells: a study of the Tn syndrome (1983) (18)
Effect of thrombin on maturing human megakaryocytes. (1993) (18)
Expression of SSEA‐I antigen (3‐fucosyl‐N‐acetyl‐lactosamine) on normal and leukaemic human haemopoietic cells: modulation by neuraminidase treatment (1984) (18)
K562 cells induced to differentiate by phorbol ester tumor promotors resist NK lysis. (1984) (18)
Generation and characterisation of Rhd and Rhag null mice (2010) (18)
LYL-1 deficiency induces a stress erythropoiesis. (2011) (17)
Hemoglobin synthesis in 7-day and 14-day-old erythroid colonies from the bone marrow of normal individuals. (1980) (17)
Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells. (1998) (17)
Hemoglobin expression in clones of K562 cell line. (1982) (17)
The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications (2019) (17)
Identification of MPL R102P Mutation in Hereditary Thrombocytosis (2017) (17)
Monoclonal antibodies specific for human platelet membrane glycoproteins bind to monocytes by focal absorption of platelet membrane fragments: an ultrastructural immunogold study. (1987) (17)
c-jun and c-fos are expressed by human megakaryocytes. (1992) (17)
Embryonic and fetal hemoglobin synthesis in K562 cell line. (1981) (17)
Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis. (2011) (17)
Uncoordinated expression of alpha-granule proteins in human megakaryocytes. (1990) (16)
[Erythropoiesis and its regulation]. (1993) (16)
Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases (2020) (16)
Immunological and cytochemical characterization of megakaryocytic lineage leukemia. (1986) (16)
Alterations of NFIA in chronic malignant myeloid diseases (2009) (16)
Reticulocytosis, hypochromia, and microcytosis: an unusual presentation of the preleukemic syndrome. (1982) (16)
Quantitative Oct4 Overproduction in Mouse Embryonic Stem Cells Results in Prolonged Mesoderm Commitment During Hematopoietic Differentiation In Vitro (2006) (16)
Compared effects of Mpl ligand and other cytokines on human MK differentiation (1998) (16)
Uncoupling in the expression of platelet GP IIb/IIIa in human endothelial cells and K562 cells: absence of immunologic crossreactivity between platelet GP IIb and the vitronectin receptor alpha chain. (1988) (16)
Effects of five recombinant hematopoietic growth factors on enriched human erythroid progenitors in serum‐replaced cultures (1989) (16)
Description of a Knock-In Mouse Model of JAK2V617F MPN Emerging from a Minority of Mutated Hematopoietic Stem Cells. (2019) (15)
Thrombopoietin (TPO) knockout phenotype induced by cross-reactive antibodies against TPO following injection of mice with recombinant adenovirus encoding human TPO. (1998) (15)
Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes. (2016) (15)
Thromboxane Synthase Has the Same Pattern of Expression as Platelet Specific Glycoproteins during Human Megakaryocyte Differentiation (2000) (15)
Expression of the c-fos protooncogene by human and murine erythroblasts. (1989) (15)
Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis (2014) (15)
Thrombopoietin from human embryonic kidney cells is the same factor as c-mpl-ligand. (1995) (15)
Fetal to adult hemoglobin switch in cultures of early erythroid precursors from human fetuses and neonates (1979) (15)
An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. (2016) (15)
Globin-chain affinity chromatography on Sepharose-haptoglobin: a new method of study of hemoglobin synthesis in reticulocytes, in bone marrow and in colonies of erythroid precursors. (2005) (15)
Expression of platelet glycoproteins by erythroid blasts in four cases of trisomy 21. (1989) (15)
Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators (2006) (14)
HLA-DR restriction in suppression of hematopoiesis by T cells from allogeneic bone marrow transplants. (1986) (14)
Pyruvate kinase synthesis and degradation by normal and pathologic cells during erythroid maturation. (1988) (14)
Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models. (2006) (14)
Association between leukemic erythroid progenitors and bone marrow macrophages. (1991) (14)
Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint (2016) (14)
MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors. (2019) (14)
Fucoidan promotes early step of cardiac differentiation from human embryonic stem cells and long-term maintenance of beating areas. (2014) (14)
Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis. (1994) (14)
Elevated HbF associated with an unstable hemoglobin, hemoglobin Saint Etienne: Hb synthesis in blood BFUe in culture. (1979) (14)
Eltrombopag, a potent stimulator of megakaryopoiesis (2016) (14)
c-mpl, the Thrombopoietin Receptor (1995) (13)
Inhibition of transferring binding and iron uptake of hematopoietic cell lines by phorbol esters. (1984) (13)
SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis (2009) (13)
New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis (2017) (13)
In vitro inhibition of hematopoiesis by HNK1, DR-positive T cells and monocytes after allogeneic bone marrow transplantation. (1987) (13)
Functional Consequences of Mutations in Myeloproliferative Neoplasms (2021) (13)
Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment (2014) (13)
Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. (2009) (13)
Protective effects of differentiation inducers on natural killer sensitivity of K 562 cells: Analysis at a single-cell level. (1983) (13)
Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. (2021) (13)
Isolation and culture of megakaryocyte precursors. (2004) (13)
Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology (2015) (13)
Autocrine regulation of terminal differentiation by interleukin-6 in the pluripotent KU812 cell line. (1990) (13)
MplK, a natural variant of the thrombopoietin receptor with a truncated cytoplasmic domain, binds thrombopoietin but does not interfere with thrombopoietin-mediated cell growth. (2002) (12)
JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML (2020) (12)
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms (MPN). (2021) (12)
Expression of a foreign protein in human megakaryocytes and platelets by retrovirally mediated gene transfer. (1999) (12)
RGS 16 is a negative regulator of SDF-1 – CXCR 4 signaling in megakaryocytes (2005) (12)
Beta-thalassemia and sickle cell disease in culture of early erythroid precursors: hemoglobin synthesis and ultrastructural study. (1981) (12)
The Notch Delta-4 ligand helps to maintain the quiescence and the short-term reconstitutive potential of haematopoietic progenitor cells through activation of a key gene network. (2014) (12)
Carboxyl-terminal-dependent recruitment of nonmuscle myosin II to megakaryocyte contractile ring during polyploidization. (2014) (12)
Myelofibrosis, JAK2 inhibitors and erythropoiesis (2013) (12)
ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies (2016) (12)
Ligand-independent Thrombopoietin Mutant Receptor Requires Cell Surface Localization for Endogenous Activity* (2009) (12)
BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. (2009) (11)
Pluripotent stem cells constitutively expressing a normal erythropoietin receptor give rise to normal hematopoiesis in lethally irradiated recipient mice. (1996) (11)
Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia (2019) (11)
A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. (2020) (11)
Embryonic stem cell differentiation to hematopoietic cells: A model to study the function of various regions of the intracytoplasmic domain of cytokine receptors in vitro. (2000) (11)
Regulation of human megakaryocytopoiesis: analysis of proliferation, ploidy and maturation in liquid cultures. (1990) (10)
Evaluation of hematopoietic potential generated by transplantation of muscle-derived stem cells in mice. (2004) (10)
Distinct localizations and roles of non‐muscle myosin II during proplatelet formation and platelet release (2015) (10)
Recurrent V75M mutation within the Wiskott–Aldrich syndrome protein: description of a homozygous female patient (2005) (10)
Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre‐leukaemic clone resulting in T2‐ALL and AML‐M0 (2016) (10)
Differential signalling of NH2-terminal flag-labelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies. (2004) (10)
Thrombopoietin responsiveness reflects the number of doublings undergone by megakaryocyte progenitors. (2004) (10)
Adenoviral supply of active transforming growth factor-beta1 (TGF-beta1) did not prevent lethality in transforming growth factor-beta1-knockout embryos. (2002) (9)
Erroneous results of 3H-thymidine incorporation are related to position of thymidine residues in oligodeoxynucleotides. (1994) (9)
Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission (2020) (9)
Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms (2021) (9)
[Mutations in TET2 in myeloid cancers]. (2009) (9)
Rifampicin-induced pure red cell aplasia. (1989) (9)
Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. (2020) (8)
Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms (2012) (8)
Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice (2015) (8)
Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor (2013) (8)
The Pediatric Acute Leukemia Fusion Oncogene ETO2-GLIS2 Increases Self-Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells-Derived Model (2019) (8)
Cellular regulation of i and I antigen expressions in human erythroblasts grown in vitro. (1981) (8)
Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms (2020) (8)
Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets? (2012) (8)
Expression of vimentin intermediate filament cytoskeleton in acute nonlymphoblastic leukemias. (1985) (8)
Efficient ex vivo expansion of NOD/SCID-repopulating cells with lympho-myeloid potential in hematopoietic grafts of children with solid tumors. (2001) (8)
Ectopic expression of the erythropoietin receptor in a murine interleukin-6-dependent plasmacytoma cell line (TEPC-2027) confers proliferative responsiveness to erythropoietin. (1997) (7)
Fetal hemoglobin synthesis in culture of early erythroid precursors (BFU‐E) from the blood of normal adults (1980) (7)
Thrombopoietin and its receptor, the proto-oncogene c-mpl (1995) (7)
Putative innate immunity of antiatherogenic paraoxanase-2 via STAT5 signal transduction in HIV-1 infection of hematopoietic TF-1 cells and in SCID-hu mice. (2010) (7)
Constitutive IL-2 expression in HTLV-I-infected leukaemic T cell lines. (1991) (7)
Beta O-thalassemia/Hb E association. Hemoglobin synthesis in blood reticulocytes and bone marrow cells fractionated by density gradient and in blood erythroid colonies in culture. (1980) (7)
Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts (2001) (7)
Preferential liver irradiation enhances hematopoiesis through a thrombopoietin-independent mechanism. (1999) (7)
Expression of platelet proteins during maturation of human megakaryocytes and of the K 562/HEL cell lines. (1986) (7)
p210BCR-ABL reprograms transformed and normal human megakaryocytic progenitor cells into erythroid cells and suppresses FLI-1 transcription (2007) (7)
JAK2V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect (2011) (7)
Association of TET2 Alterations with NPM1 Mutations and Prognostic Value in De Novo Acute Myeloid Leukemia (AML). (2009) (7)
Proteasome Inhibitor Bortezomib Can Inhibit Bone Marrow Fibrosis Development in a Murine Model of Myelofibrosis. (2005) (7)
Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice (2018) (6)
Genesis of clone size heterogeneity in megakaryocytic and other hemopoietic colonies: the stochastic model revisited. (2001) (6)
Acceleration of the hemoglobin switch in cultures in neonate erythroid precursors by adult cells (1980) (6)
The NF-κB pathway is rarely spontaneously activated in mantle cell lymphoma (MCL) cell lines and patient's samples. (2014) (6)
Zyxin is up-regulated during megakaryocytic differentiation of human UT-7/c-mpl cells. (2004) (6)
SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN) (2020) (6)
TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. (2020) (6)
Diagnosis of megakaryoblastic leukemias. (1983) (5)
Pyruvate Kinase Synthesis and Degradation by Normal and Pathologic Cells During Erythroid Maturation (1988) (5)
A new efficient tool for non‐invasive diagnosis of fetomaternal platelet antigen incompatibility (2020) (5)
Lyl-1 regulates primitive macrophages and microglia development (2021) (5)
Expression of blood group A antigen during erythroid differentiation in A1 and A2 subjects. (1987) (5)
Production of IL-12 by Human Dendritic B p 50 in the κ Requirement for NF-RNA Interference Shows Critical Vainchenker and (2003) (5)
JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice (2015) (5)
Elevated Hb F associated with beta-thalassaemia trait: haemoglobin synthesis in reticulocytes and in blood BFU-E. (2009) (5)
BCR-ABL Fails to Inhibit Apoptosis in U937 Myelomonocytic Cells Expressing a Carboxyl-Terminal Truncated Stat5 (2001) (5)
[Hematopoiesis and its regulation. Comparison between erythropoiesis and megakaryocytopoiesis]. (1994) (4)
Congenital dyserythropoietic anemia type III. studies on erythroid differentiation of blood erythroid progenitor cells (BFUE) in vitro. (1980) (4)
Inferring the initiation and development of myeloproliferative neoplasms (2022) (4)
Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms (2021) (4)
Differential Impact of Interferon Alpha on JAK2V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN (2018) (4)
Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis (2021) (4)
In Vitro Effects of Mpl Ligand on Human Hemopoietit Progenitor Cells (1997) (4)
Frequent Inactivating Mutations of TET2 and CBL Are Associated with Acquired Uniparental Disomy in Atypical Chronic Myeloid Leukemia and Related Disorders. (2009) (4)
From the v-mpl oncogene to thrombopoietin. (1995) (4)
Quantitative and qualitative in vitro analysis of the stem cell potential of hematopoietic cells purified from murine skeletal muscle (2007) (4)
Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model (2022) (4)
Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN? (2012) (4)
Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML (2010) (4)
Congenital Dyserythropoietic Anaemia Type I: Absence of Clonal Expression in the Nuclear Abnormalities of Cultured Erythroblasts (1980) (4)
Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors (2007) (4)
Hb Switching in neonatal cultures. Increase of Hb A synthesis in presence of an erythroid potentiating activity (EPA) (1982) (4)
Absence of erythroblastic islands in plasma clot culture and their possible reconstitution after clot lysis. (1979) (4)
The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. (2007) (4)
Hemoglobin expression in clones of K-562 cell line. (1982) (3)
A gamma and G gamma globin chain synthesis in BFU-E colonies from adult, newborn, and fetal subjects and from thalassemic patients. (1980) (3)
Will Imitanib Be Useful for Patients with Polycythemia Vera (2005) (3)
CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. (2021) (3)
TET2 loss, a rescue of JAK2V617F HSCs. (2015) (3)
Change in i-antigen expression of erythrocytes during in vivo aging. (1981) (3)
Stromal cells maintain the radioprotective capacity of CFU-S during retroviral infection. (1996) (3)
Role of Rho-GTPases in megakaryopoiesis (2021) (3)
Myelofibrosis: Experimental models and human studies (1998) (3)
The Hematopoietic Reconstitution Defect of Mice Lacking CXCR4 Is Related to an Altered Retention of Hematopoietic Cells in the Bone Marrow. (2004) (3)
[Megakaryopoiesis: regulation of platelet production by thrombopoietin]. (2013) (3)
A New Congenital Dysmegakaryopoietic Thrombocytopenia ( Paris-Trousseau ) Associated With Giant Platelet &-Granules and Chromosome 11 Deletion at l lq 23 (2002) (3)
JAK2 Activation Stimulates Homologous Recombination and Genetic Instability. (2007) (3)
Megakaryocytes tame erythropoiesis with TGFβ1. (2020) (3)
Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs) (2022) (3)
ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies (2021) (3)
Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis (2013) (3)
Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms. (2022) (3)
Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML) (2012) (3)
[Thrombopoietin and megakaryocyte differentiation]. (1998) (3)
[In cauda venenum or the importance of TET(2)]. (2011) (2)
Growth of Erythroid Colonies in Chronic Myelogenous Leukemia Is Independent of Erythropoietin Only in the Presence of Steel Factor (1994) (2)
Comparative patterns of i-antigen expression, F-cell frequency and Hb A2 level in acute myeloid leukemia and in acute lymphoid leukemia. (1981) (2)
[Differentiation of human megakaryocytes in culture starting from the primordial circulating cells in the newborn]. (1978) (2)
Inhibition of TET2 Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine Disturbs Myelopoiesis and Granulo-Monocytic Differentiation. (2010) (2)
[Fli1 haploinsufficiency underlies Paris-Trousseau thrombopenia]. (2004) (2)
Faculty Opinions recommendation of Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. (2016) (2)
Unfractionated peripheral blood stem cell autografts and CD(34+)-enriched autografts have similar long-term culture initiating capacity in multiple myeloma. (1999) (2)
during erythroid maturation Pyruvate kinase synthesis and degradation by normal and pathologic cells (2011) (2)
Mpl ligand or thrombopoietin: Biological activities (1998) (2)
PPAR-y agonists promote the resolution of myelofibrosis in preclinical models. (2021) (2)
Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes (2022) (2)
CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. (2020) (2)
Early erythroid markers as probes for normal and leukaemic erythroid differentiation. (1987) (2)
Dysregulated Mpl-Ligand production by hemopoietic cellsinduces a fatal myeloproliferative syndrome in mice (1997) (2)
An inherited gain‐of‐function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms (2022) (2)
Acquired TET 2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T 2-ALL and AML-M 0 (2017) (2)
14 In Vitro Effects of Mpl Ligand on Human Hemopoietic Progenitor Cells (2)
[A case of erythoblastic leukemia with basophilic reaction]. (1991) (2)
Dual role of EZH2 on megakaryocyte differentiation. (2021) (2)
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lympho-myeloid progenitor in polycythemia vera and idiopathic myelofibrosis Short title: JAK2 V617F in lympho-myeloid progenitor cells (2006) (2)
Aging of Bone Marrow Microenvironment Promotes Myeloid Bias of Hematopoietic Progenitors and Is a Target in Age-Related Myeloproliferative Neoplasms (2018) (2)
Biological drivers of clinical phenotype in myelofibrosis (2022) (2)
EZH2: a molecular switch of the MPN phenotype. (2016) (2)
Can Peg-Interferon (IFN) α-2a Eradicate JAK2V617F-Positive Bone Marrow Progenitors in Polycythemia Vera (PV)? (2008) (2)
Defect in Ribosome Biogenesis Contributes to Impaired Megakaryopoiesis in Primary Myelofibrosis (2014) (2)
Interferon-Alpha Preferentially Targets JAK2V617F-Positive Rather Than Wild-Type Early Progenitor Cells in Myeloproliferative Disorders. (2009) (2)
CK2: a key regulator of thrombopoiesis. (2017) (2)
William defects in the contractile ring and Rho / Rock signaling Megakaryocyte endomitosis is a failure of late cytokinesis related to (2008) (1)
The EHA Research Roadmap: Normal Hematopoiesis (2021) (1)
NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN) (2020) (1)
The megakaryocyte: a cell with 3 faces as a mythic god? (2021) (1)
[Mpl ligand (thrombopoietin) and platelet regulation]. (1996) (1)
GATA-1 and NOTCH signaling Ikaros inhibits megakaryopoiesis through functional interaction with (2013) (1)
MEGAKARYOCYTIC ORIGIN OF PLATELET HLA CLASS I ANTIGEN (1987) (1)
1 Transgenic mouse models demonstrate the Carboxyl-terminal depended recruitment of non-muscle myosin II to megakaryocyte contractile ring during polyploidization (2014) (1)
Constitutive Heterozygous Expression of JAK2V617F Mutated Kinase Triggers Severe Myeloproliferative Disorder in Knock-in Mice. (2009) (1)
In vitro and in vivo evaluation of the haematopoietic potential of skeletal muscle in a non-human primate model (2008) (1)
From Hematopoietic Stem Cells to Megakaryocytes and Platelets (2008) (1)
Stromal Microenvironment Regulates Progenitor Survival through Nitric Oxide Production. (2009) (1)
[Ex-vivo expansion of hematopoietic stem cells: study in the primate model]. (1999) (1)
Faculty Opinions recommendation of Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2016) (1)
Increased Myelofibrosis in Thrombospondin-1-Null Mice Is Associated with Enhanced TGF-β1-Mediated Response by Bone Marrow Fibroblasts (2008) (1)
Gﬁ-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells (2005) (1)
Cellular and molecular mechanisms of haemoglobin switching in man. (1982) (1)
Mpl-Ligand and the Regulation of Megakaryocytopoiesis: Cellular Aspects and Regulation (1996) (1)
Study of V617F JAK2-Positive and JAK2-Negative Patients within 18 Families with Myeloproliferative Disorders (MPD): Disease Characteristics and Evolution, EPOR and MPL Analysis. (2006) (1)
Peroxidatic activity distinct from myeloperoxidase in human monocytes cultured in vitro and in alveolar macrophages. (1982) (1)
The Hematopoietic Stem Cell Compartment Is Different in Polycythemia Vera and Idiopathic Myelofibrosis. (2007) (1)
The ETO2-GLIS2 Fusion Oncogene Alters Early Human Hematopoiesis in an Induced Pluripotent Stem Cells-Derived Model of Pediatric Acute Megakaryoblastic Leukemia (2017) (1)
New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia (2016) (1)
Severe Thrombocytopenia with Impaired Megakaryocytopoiesis in a Family with von Willebrand Disease Type 2B. (2005) (1)
PS1498 INCREASED RHOA ACTIVITY DUE TO A DISRUPTED FILAMIN A/ALPHAIIBBETA3 INTERACTION INDUCES MACROTHROMBOCYTOPENIA (2019) (1)
Faculty of 1000 evaluation for Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. (2018) (1)
The role of phorbol esters in the control of the proliferation and differentiation of hematopoietic cells. (1983) (1)
A MONOCLONAL ANTIBODY AGAINST AN ERYTHROID ONTOGENIC ANTIGEN IDENTIFIES GP IV ON HUMAN PLATELETS (1987) (1)
46/1 Haplotype Permits to Follow JAK2 Homologous Recombination: Modeling JAK2V617F clonal Architecture in PV Patients (2012) (1)
Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms (2021) (1)
Acceleration of the hemoglobin switch in cultures in neonate erythroid precursors by adult cells. (1980) (1)
Cytogenetic study of myeloid and erythroid colonies in chronic myeloid leukaemia with stable Ph1 mosaicism (1987) (1)
SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes (2021) (1)
CXCR7 Expression Restricts CXCR4/SDF-1 Mediated Hematopoietic-Supporting Activity of Stromal Cells by Decreasing Extracellular SDF-1 Availability. (2009) (1)
The myeloproliferative disease JAK2 V617F mutant cannot be regulated by SOCS proteins (2007) (1)
[Hematopoietic stem cells]. (2001) (1)
Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML) (2012) (1)
[Treatment of chronic autoimmune thrombopenic purpura with intravenous immunoglobulins. Study of 18 cases]. (1983) (1)
Heterogeneous Distribution of the JAK2 Val617Phe Activating Mutation in Familial Myeloproliferative Disorders. (2005) (1)
Modeling JAK2V617F Heterozygous and Homozygous Mutations by Using Induced Pluripotent Stem Cells Derived From Myeloproliferative Neoplasms Patients (2012) (1)
Faculty of 1000 evaluation for A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. (2018) (0)
Functional Correction of Lymphocytes and Dendritic Cells of Patients with WAS or XLT, Using Lentiviral Vectors Targeting the Expression of WAS Protein to Hematopoietic Cells. (2005) (0)
Critical role of the HDAC6–cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect (2017) (0)
Megakaryocyte (MK) clone size is inversely related to CFU-MK responsiveness to thrombopoietin (TPO) (2001) (0)
undergone by megakaryocyte progenitors Thrombopoietin responsiveness reflects the number of doublings (2013) (0)
Faculty of 1000 evaluation for Hepatic thrombopoietin is required for bone marrow hematopoietic stem cell maintenance. (2018) (0)
Faculty Opinions recommendation of Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. (2014) (0)
Lyl-1 marks and regulates primitive macrophages and microglia development (2020) (0)
Pericyte Coverage of Abnormal Blood Vessels in Myelofibrosis Bone Marrows. (2005) (0)
MAP Kinase Signaling Pathway Induced by TPO Is a Negative Regulator of Proplatelet Formation in Human Megakaryocytes. (2006) (0)
Faculty Opinions recommendation of Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. (2019) (0)
Implication of HIF-1α but Not HIF-2α in the Hypoxic Response of Human Hematopoietic Progenitors. (2004) (0)
[Physiopathologic and therapeutic importance of animal models of hemoglobinopathies]. (1993) (0)
Comparative analysis of the hematopoietic potential of human embryonic and adult muscle (2003) (0)
of the preleukemic syndrome Reticulocytosis, hypochromia, and microcytosis: an unusual presentation (2011) (0)
T-lymphocyte chemotaxis induced - The interaction between Cdc42 and WASP is required for SDF-1 (2013) (0)
A Murine Stromal Cel l Line Allows the Proliferation of Very Primitive Human CD 34 +-I-/ CD 38-Progenitor Cel l s in Long-Term Cultures and Semisol id Assays (2003) (0)
In vitro Inhibition of Hematopoiesis by T3, HNK1, T8, DR Positive T Cells after Bone Marrow Transplantation (1985) (0)
differentiation EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic (2013) (0)
Detection of JAK2 V617F in the Diagnosis of Erythrocytosis: Feasibility and Diagnostic Value in Clinical Practice. (2005) (0)
Faculty of 1000 evaluation for Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. (2018) (0)
Brief Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia (2007) (0)
Faculty Opinions recommendation of Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms. (0)
Faculty of 1000 evaluation for Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke's encephalopathy. (2018) (0)
P53 deletion and NrasG12D cooperate for AML. (2017) (0)
megakaryocytes Platelet formation is the consequence of caspase activation within (2013) (0)
P051 TET2 is a tumor suppressor gene targeted in myeloid disorders (2009) (0)
Faculty Opinions recommendation of LKB1/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms. (2021) (0)
Identification of a JAK2 mutation at vaguez 'polyglobuli (2005) (0)
Faculty of 1000 evaluation for A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. (2018) (0)
Identification of a jak2 mutante implied in the polycythemia vera (2005) (0)
Faculty of 1000 evaluation for A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. (2018) (0)
after transplantation of human cord blood mononuclear cells and nonobese diabetic-severe combined immunodeficiency mice immune- deficient CB17-severe combined immunodeficiency mice Phenotype and function of human hematopoietic cells engrafting (2011) (0)
Faculty Opinions recommendation of Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. (2020) (0)
Faculty Opinions recommendation of JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. (2020) (0)
JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines. (2006) (0)
Identiﬁcation of Lymphomyeloid Primitive Progenitor Cells in Fresh Human Cord Blood and in the Marrow of Nonobese Diabetic–Severe Combined Immunodeﬁcient (NOD-SCID) Mice Transplanted with Human CD34 (cid:49) Cord Blood Cells (1999) (0)
p210 BCR-ABL by down Regulating FLI-1 Reprograms Megakaryocytic Progenitors to the Erythroid Lineage. (2005) (0)
Pathological activation of TpoR and JAK2 STAT5 pathway by frameshift mutants of murine calreticulin (2016) (0)
Faculty Opinions recommendation of SIRT1 activation disrupts maintenance of myelodysplastic syndrome stem and progenitor cells by restoring TET2 function. (2019) (0)
Faculty Opinions recommendation of Lung megakaryocytes are immune modulatory cells. (2021) (0)
Expression of Vimentin Intermediate Filament Cytoskeleton in (2016) (0)
Recombinant Adenovirus Encoding Human TPO TPO Following Injection of Mice with Induced by Cross-Reactive Antibodies Against Thrombopoietin ( TPO ) Knockout Phenotype (1998) (0)
Membrane and cytoplasmic phenotypes of small megakaryocyte precursors maturing in culture from normal human megakaryocyte progenitor cell (1983) (0)
Faculty Opinions recommendation of A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. (2019) (0)
Megakaryocyte differentiation and regulation (2004) (0)
Evidence That the MPL 515L and 515K Mutations Occur in a Lympho-Myeloid Progenitor in Idiopathic Myelofibrosis and Are Associated with TPO Hypersensitivity. (2006) (0)
Thrombopoietin dose-response curves reflect the number of doublings undergone by human megakaryocyte progenitors (2004) (0)
Faculty Opinions recommendation of Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. (2016) (0)
Faculty of 1000 evaluation for Methotrexate is a JAK/STAT pathway inhibitor. (2018) (0)
Thrombopoietin (Mpl-ligand) and the regulation of platelet production. (1997) (0)
Faculty Opinions recommendation of MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. (2016) (0)
Constitutive TGF-β1 Deficiency Induces a Defect in Hematopoietic Stem/Progenitor Cell Compartment in Fetus and Neonate. (2008) (0)
Faculty Opinions recommendation of Classification and personalized prognosis in myeloproliferative neoplasms. (2018) (0)
Monoclonal antibodies against adult and fetal red blood cells (1986) (0)
A Somatic Mutation in the G6PD Gene in Hematopoietic Cells Causes a Chronic Haemolytic Anemia. (2009) (0)
Study of hemoglobin synthesis by affinity chromatography on Sepharose haptoglobin. (1981) (0)
OTT-MAL Activates the Notch Signaling Transcription Factor RBPJ and Cooperates with Mutant MPL to Induce Acute Megakaryoblastic Leukemia (2008) (0)
High Levels of Thrombopoietin Impair the Promotion of Myelofibrosis by Monocyte/Macrophage Dysfunctions Do Not (2006) (0)
23 DOWN-REGULATION OF MIR150 PROMOTES THE ACCUMULATION OF CLASSICAL MONOCYTES, A CHARACTERISTIC FEATURE OF CHRONIC MYELOMONOCYTIC LEUKEMIA (2015) (0)
Faculty of 1000 evaluation for Efficacy of baricitinib in the treatment of rheumatoid arthritis. (2018) (0)
osteosclerosis induced by high thrombopoietin levels in mice Proteasome inhibitor bortezomib impairs both myelofibrosis and (2013) (0)
Faculty Opinions recommendation of Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. (2020) (0)
Abstract 2022: P53-dependent thrombocytopenia induced by the histone deacetylase inhibitor S78454 (2012) (0)
X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome A defect in hematopoietic stem cell migration explains the nonrandom (2012) (0)
Predicting the Long-Term Efficacy of Ifnα in JAK2V617F and Calr-Mutated MPN Patients (2019) (0)
Activation of p53 Pathway In Erythroid Precursor Cells of Diamond-Blackfan Anemia Leads to Two Distinct Phenotypes (2010) (0)
Defects in Filamin A (FLNa) in Women with X-Linked Filaminopathies: Abnormalities in Platelet Production and Platelet Function (2011) (0)
Identification Of Human Megakaryocytes Grown In Vitro By Two Monoclonal Platelet Antibodies (1981) (0)
Following the in vivo expansion of a myeloproliferative disease (2017) (0)
Faculty of 1000 evaluation for Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings. (2018) (0)
Platelet Phenotype and Thrombosis In JAK2V617F Mice (2011) (0)
CXCR4 Blockade as a New Targeted Therapy for Acute Myeloide Leukemia Characterised by High Cell Surface Density of CXCR4. (2009) (0)
[Erythrocyte receptors of insulin]. (1982) (0)
Human Embryonic Stem Cell-Derived and Fetal Macrophages Exhibit Mainly Features of Alternative (M2) Polarization. (2009) (0)
Faculty of 1000 evaluation for Gli1(+) mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target. (2018) (0)
New Insights into the Molecular Pathogenesis of Bcr-Abl–Negative Myeloproliferative Disorders (2009) (0)
from adults and neonates Different expression of CD41 on human lymphoid and myeloid progenitors (2013) (0)
Regulation of i-and l-Antigen Expression in the K 562 Cell Line 1 (2006) (0)
Faculty Opinions recommendation of Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. (2016) (0)
Thrombopoietin (TPO) responsiveness reflects the number of doublings (NbD) undergone by human megakaryocyte (MK) progenitors (2003) (0)
Use Of 46/1 Haplotype Permits To Follow JAK2V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment (2013) (0)
factor as c-mpl-ligand (letter) Thrombopoietin from human embryonic kidney cells is the same (2011) (0)
Faculty of 1000 evaluation for Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. (2018) (0)
JAK/STAT Signalling and Haematological Malignancies (2015) (0)
ETO2-GLIS2 Controls Differentiation Arrest and Self-Renewal through Aberrant Enhancers Regulation in Pediatric Leukemia (2016) (0)
MPL/JAK2: from one signaling pathway to several disorders (2016) (0)
Mpl Expression and Functional Role in Human Megakaryocytopoiesis (1997) (0)
Faculty Opinions recommendation of Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia. (2013) (0)
From 1 to 2 mutated JAK2: the road from ET to PV (2006) (0)
Faculty of 1000 evaluation for The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. (2018) (0)
Faculty of 1000 evaluation for Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. (2018) (0)
Role of cytokines on in vitro platelet production (1997) (0)
Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage (2019) (0)
Induced pluripotent stem cells : from history to applications (2013) (0)
PRODUCTION AND LOCALISATION OF ALPHA-GRANULE PROTEINS IN MATURING MEGAKARYOCYTES: AN OVERVIEW ON ULTRA-STRUCTURAL ASPECTS OF MEGAKARYOCYTE MATURATION (1987) (0)
Faculty Opinions recommendation of The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. (2016) (0)
Faculty Opinions recommendation of Induction of functional platelets from mouse and human fibroblasts by p45NF-E2/Maf. (2013) (0)
Ligand-Independent MPLW515L Activity Requires Cell Surface Localization (2008) (0)
Faculty of 1000 evaluation for Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. (2018) (0)
Faculty Opinions recommendation of DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. (2016) (0)
Impaired Erythropoiesis in LYL-1 Deficient Mice. (2008) (0)
University of Birmingham Critical role of the HDAC6-cortactin axis in human-megakaryocytes maturation leading to a proplatelet-formation defect (2017) (0)
Faculty Opinions recommendation of The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. (2016) (0)
Faculty of 1000 evaluation for Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia. (2018) (0)
Faculty Opinions recommendation of Population dynamics of normal human blood inferred from somatic mutations. (2018) (0)
Faculty Opinions recommendation of IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. (2016) (0)
Efficient mobilization and transduction of WASP-deficient haematopoietic cells in a murine model (2012) (0)
Clinical Grade Ex-Vivo Expansion of Granulomonocytic Cells and Progenitors Using High-Dose SCF and G-CSF without Exhaustion of Stem Cell Activity. (2004) (0)
Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment (2018) (0)
HSP70, the Key to Account for Erythroid Tropism of Diamond-Blackfan Anemia? (2015) (0)
TET2 Haploinsufficiency Alters Reprogramming into Induced Pluripotent Stem Cells (2020) (0)
Faculty of 1000 evaluation for Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. (2018) (0)
[Cellular regulation of the expression of i and I antigens during the in vitro differentiation of BFU-E]. (1980) (0)
severe thrombocytopenia Impaired megakaryocytopoiesis in type 2B von Willebrand disease with (2011) (0)
ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis (2022) (0)
Mpl ligand (thrombopoietin) and regulation of Ratelet production (1995) (0)
1616. Mechanism of Thrombocytopenia Induced by Oxazolidinones Antibiotics (Linezolid, Tedizolid): Demonstration of Impairment of Megakaryocyte Differentiation From Human Hematopoietic Stem Cells associated with Mitochondrial Toxicity (2020) (0)
Faculty of 1000 evaluation for Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. (2018) (0)
Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis (2020) (0)
CXCR4 Invalidation Limits the MLL-ENL Induced Leucemogenesis in Vivo (2012) (0)
amplification Megakaryocyte polyploidization is associated with a functional gene (2013) (0)
Identification of a mutation of JAK2 in polycythemia INVOLVED Vaquez (2004) (0)
Stromal microenvironment regulates progenitor survival through nitric oxide production (2010) (0)
Abnormal Proplatelet Formation and Myosin Activation Status in Patients with MYH9-Related Syndrome (2011) (0)
Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms (2014) (0)
Faculty Opinions recommendation of Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. (2016) (0)
Haematopoiesis during HIV infection (1995) (0)
[Hope and limits in cell therapies]. (2005) (0)
Identification of a mutation of JAK2 involved in polycythemia vazquez. (2005) (0)
Etienne: Hb synthesis in blood BFUe in culture Elevated HbF associated with an unstable hemoglobin, hemoglobin Saint (2012) (0)
Composition for the production of therapeutics in vivo. (1993) (0)
Adenoviral Mediated TGF-β1inhibition in a Murine Model of Myelofibrosis Can Prevent and Cure Bone Marrow Fibrosis Development. (2004) (0)
In Vitro Knock-Down of Myh9 Leads to a Myh9-Related Disorder Phenotype in Human Megakaryocytes. (2009) (0)
TGF-β1: Key role in myelofibrosis (2003) (0)
Faculty of 1000 evaluation for Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. (2018) (0)
Faculty of 1000 evaluation for A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). (2018) (0)
Faculty of 1000 evaluation for Jak1 integrates cytokine sensing to regulate hematopoietic stem cell function and stress hematopoiesis. (2018) (0)
TET2 Favors Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells (2011) (0)
Mathematical modelling, selection and hierarchical inference to determine the minimal dose in IFN$\alpha$ therapy against Myeloproliferative Neoplasms (2021) (0)
Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification (2022) (0)
Ultrastructural Analysis of Organelles Produced in Megakaryocytes Cultured from Human Stem Cells (1979) (0)
osteosclerosis in mice overexpressing TPO Stimulation of osteoprotegerin production is responsible for (2013) (0)
Faculty of 1000 evaluation for Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. (2018) (0)
[From giant to micro: a platelet story]. (2008) (0)
Faculty Opinions recommendation of Impact of inflammation on myeloproliferative neoplasm symptom development. (2016) (0)
Faculty Opinions recommendation of Life histories of myeloproliferative neoplasms inferred from phylogenies. (2022) (0)
ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML (2018) (0)
Hb Kokura alpha 2 47 (CE5) Asp----Gly beta 2 in a French Jewish family. (1986) (0)
[Properties and biological roles of TET proteins during embryogenesis and in hematopoiesis]. (2015) (0)
Comparative Single Cell Analysis of Side Population (SP) / CD45+ Cells from Marrow and Skeletal Muscle Reveals Evidence of Genuine Stem Cell Function and Multilineage Differentiation Ability in Muscle-Resident Stem Cells. (2004) (0)
Faculty Opinions recommendation of U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. (2016) (0)
C020 Prevalence of TET2 mutations in MDS (2009) (0)
Novel Mutations: Dissecting Pathogenetic Contribution (2010) (0)
L07.03 JAK2 INHIBITORS: PRESENT AND FUTURE (2013) (0)
Faculty Opinions recommendation of Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets. (2020) (0)
Faculty Opinions recommendation of Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. (2016) (0)
Faculty Opinions recommendation of EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. (2019) (0)
Faculty of 1000 evaluation for Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. (2018) (0)
In VitroandIn VivoInteractions between Stromal and Leukemic Cells (2020) (0)
Serum Replacement in Culture of Human Erythroid and Megakaryocytic Precursors (1983) (0)
Faculty of 1000 evaluation for Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. (2018) (0)
Microarray Functional Comparison of CD34+ and Megakaryocytic Cell Transcriptomes in Myeloid Metaplasia with Myelofibrosis. (2005) (0)
SOCS3 Promoter Methylation Is Not Involved in Primitive Myelofibrosis Megakaryocytic Spontaneous Growth (2008) (0)
Review Oncogenic mechanisms in myeloproliferative disorders (2006) (0)
F-cells are preferentially distributed among high density erythrocytes. (1981) (0)
Leukemic Human Erythroid Differentiation Early Expression of Glycophorin C during Normal and Updated Version (2006) (0)
Role of the Transcription Factor LYL-1 in the Adult and Fetal Hematopoietic Stem Cells. (2004) (0)
JAK2 V617F mutation and the myeloproliferative disorders (2006) (0)
Pure Heterozygous and Mixed JAK2 V617F Genotypes Result in Distinct Mechanisms of Erythrocytosis in Polycythemia Vera. (2006) (0)
Faculty of 1000 evaluation for Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade. (2018) (0)
Brief report Myeloproliferative neoplasm induced by constitutive expression of JAK2 V617F in knock-in mice (2010) (0)
IFN: Jekyll and Hyde. (2021) (0)
Supplementary Figure Legend (2013) (0)
Faculty Opinions recommendation of JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. (2016) (0)
Faculty Opinions recommendation of Somatic mutations and cell identity linked by Genotyping of Transcriptomes. (2019) (0)
Faculty of 1000 evaluation for JAK inhibition impairs NK cell function in myeloproliferative neoplasms. (2018) (0)
Hématopoïèse au cours de l'infection VIH (1995) (0)
Role of caspases in platelet formation (2003) (0)
Interest of the quantification of platelet glycoproteins by flow cytometry in the establishment of constitutional macrothrombocytopenias (2009) (0)
Caspase Activated Rock-1 Allows Erythroblasts Enucleation Independently of Cytokine Signaling (2008) (0)
1017 – INVESTIGATING THE MECHANISMS OF IFNALPHA THERAPY IN JAK2V617F AND CALR MUTATED MYELOPROLIFERATIVE NEOPLASMS (2020) (0)
RUNX1-Induced Silencing of Non-Muscle Myosin Iib (MYH10) Is Required for Megakaryocyte Polyploidization (2011) (0)
Techniques for Characterization of Leucocyte Antigens and Utilization of Antibodies in Therapy (1984) (0)
Faculty Opinions recommendation of Mitochondrial fragmentation triggers ineffective hematopoiesis in myelodysplastic syndromes. (2021) (0)
Faculty of 1000 evaluation for Ruxolitinib versus standard therapy for the treatment of polycythemia vera. (2018) (0)
families with myeloproliferative disorders Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 (2013) (0)
Myeloproliferative Syndrome in Mice High Thrombopoietin Production by Hematopoietic Cells Induces a Fatal (2013) (0)
Faculty of 1000 evaluation for Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. (2018) (0)
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice. (2023) (0)
differentiation megakaryocyte progenitors and late stages of megakaryocyte Mammalian target of rapamycin (mTOR) regulates both proliferation of (2012) (0)
Faculty Opinions recommendation of Monogenic and polygenic inheritance become instruments for clonal selection. (2020) (0)
De Novo ABL Kinase Domain Mutations in Murine Bone Marrow Cells Retrovirally Transduced with Wild-Type p210 BCR-ABL and Amplified in Culture with Imatinib Mesylate. (2004) (0)
Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells (2016) (0)
In vivo monitoring of Polycythemia Vera development reveals carbonic anhydrase 1 as a potent therapeutic target. (2022) (0)
Eto2-Glis2 Recruits Eto2/Erg Complex at Super-Enhancers to Control Transcription and Drive Leukemic Properties in Pediatric Acute Megakaryoblastic Leukemia (2017) (0)
associated neutropenia cytotoxic activities of granular cells and evaluation of their role in The syndrome of T8 hyperlymphocytosis: variation in phenotype and (2011) (0)
WASP-deficient hematopoietic progenitor cells mobilize in response to G-CSF and can restore hematopoiesis in mice (2008) (0)
A Subset of Monocytic Cells Derived From Human Embryonic Stem Cells Can Give Rise to Mesenchymal Stromal Cells (2011) (0)
JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms (2022) (0)
Modeling Acute Megakaryoblastic Leukemia of Down Syndrome Using Induced Pluripotent Stem Cells (2020) (0)
Canonical NF-kB Pathway Is Not Constitutively Activated and May Not Be the Major Bortezomib Target in Mantle Cell Lymphoma (MCL). (2006) (0)
Faculty of 1000 evaluation for Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. (2018) (0)
Faculty of 1000 evaluation for A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. (2018) (0)
Faculty Opinions recommendation of Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. (2016) (0)

This paper list is powered by the following services:

Other Resources About William Vainchenker

What Schools Are Affiliated With William Vainchenker?

William Vainchenker is affiliated with the following schools:

William Vainchenker's Academic­Influence.com Rankings